1. Inhibition of Leukotriene A 4 Hydrolase Suppressed Cartilage Degradation and Synovial Inflammation in a Mouse Model of Experimental Osteoarthritis.
- Author
-
Wu X, Sun AR, Crawford R, Xiao Y, Wang Y, Prasadam I, and Mao X
- Subjects
- Animals, Humans, Male, Mice, Arthritis, Experimental metabolism, Disease Models, Animal, Leukotriene B4 metabolism, Receptors, Leukotriene B4 metabolism, Synovitis, Cartilage, Articular metabolism, Cartilage, Articular pathology, Chondrocytes metabolism, Chondrocytes pathology, Epoxide Hydrolases metabolism, Osteoarthritis metabolism
- Abstract
Objective: Chronic inflammation plays an important role in the osteoarthritis (OA) pathology but how this influence OA disease progression is unclear. Leukotriene B4 (LTB
4 ) is a potent proinflammatory lipid mediator generated from arachidonic acid through the sequential activities of 5-lipoxygenase, 5-lipoxygenase-activating protein, Leukotriene A4 hydrolase (LTA4 H) and its downstream product LTB4 . The aim of this study is to investigate the involvement and the potential therapeutic target of the LTB4 pathway in OA disease progression., Design: Both clinical human cartilage samples ( n = 7) and mice experimental OA models ( n = 6) were used. The levels of LTA4 H and leukotriene B4 receptor 1 were first examined using immunostaining in human OA/non-OA cartilage and mice experimental OA models. We also determined whether the LTA4 H pathway was associated with cartilage degeneration and synovitis inflammation in OA mice models and human articular chondrocytes., Results: We found that both LTA4 H and LTB4 receptor (BLT1) were highly expressed in human and mice OA cartilage. Inhibition of LTA4 H suppressed cartilage degeneration and synovitis in OA mice model. Furthermore, inhibition of LTA4 H promoted cartilage regeneration by upregulating chondrogenic genes expression such as aggrecan ( ACAN ), collagen 2A1 ( COL2A1 ), and SRY-Box transcription factor 9 ( SOX9 )., Conclusions: Our results indicate that the LTA4 H pathway is a crucial regulator of OA pathogenesis and suggest that LTA4 H could be a therapeutic target in combat OA., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.- Published
- 2024
- Full Text
- View/download PDF